BLAINJECTIONINJECTABLE
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HERCESSI (trastuzumab-strf) is a monoclonal antibody biosimilar approved in April 2024 as a referential biologic targeting HER2-positive cancers. It is an alternative to reference trastuzumab (Herceptin) with equivalent mechanism and clinical efficacy. The drug is administered intravenously to patients with HER2-overexpressing breast cancer and gastric cancers.
Growth
Early-stage biosimilar in growth phase with moderate competitive pressure (30% threat level); brand team will focus on market penetration and payer coverage strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HERCESSI positions you in a biosimilar growth trajectory with emphasis on competitive market penetration, payer negotiation, and manufacturing scale-up. The role is ideal for professionals seeking experience in competitive generics/biosimilar dynamics and mature market strategy rather than novel drug discovery or early-stage development.
Brand ManagerMarket Access Manager
Worked on HERCESSI at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.